Turning G proteins on and off using peptide ligands

William W. Ja1,†, Ofer Wiser2,†,‡, Ryan J. Austin1, Lily Y. Jan2, and Richard W. Roberts3,*

1Division of Biology, California Institute of Technology, Pasadena, CA, 91125, USA
2Howard Hughes Medical Institute, Departments of Physiology and Biochemistry, University of California, San Francisco, 1550 4th Street, San Francisco, CA 94143, USA
3University of Southern California, Department of Chemistry and Mork Family Department of Chemical Engineering, Los Angeles, CA, 90089, USA

Abstract

Intracellular Gα subunits represent potential therapeutic targets for a number of diseases. Here we describe three classes of new molecules that modulate G protein signaling by direct targeting of Gα. Using mRNA display, we have identified unique peptide sequences that bind Gαi1. Functionally, individual peptides were found that either enhance or repress basal levels of G protein-activated inwardly rectifying potassium (GIRK) channel signaling—a downstream effector of G protein activation—indicating that the peptides directly turn G proteins on or off in vivo. A third functional class acts as a signaling attenuator—basal GIRK channel activity is unaffected but responses to repeated G protein activation are reduced. These data demonstrate that G protein-directed ligands can achieve similar physiological effects as those resulting from classical receptor targeting and may serve as leads for developing new classes of therapeutics.

Heterotrimeric guanine nucleotide-binding proteins (G proteins), composed of α, β, and γ subunits, play a critical role in communicating extracellular signals to intracellular signal transduction pathways through membrane-spanning G protein-coupled receptors (GPCRs) (1,2). Activation of GPCRs by extracellular agonists triggers the exchange of GDP with GTP in the Gα subunit and dissociation of Gβγ heterodimers from Gα-GTP, which both regulate multiple effectors. Gβγ subunits, for example, can directly regulate adenyl cyclase, phospholipase Cβ isozymes, and GIRK channels (3). GTP hydrolysis by the inherent Gα guanosine triphosphatase (GTPase) activity, a reaction catalyzed by various GTPase-activating proteins (GAPs), returns Gα to the GDP-bound state and results in reassociation with Gβγ and termination of signaling.

Intracellular G proteins have potential as drug targets for a number of diseases (4–7). The large number of possible combinations of α, β, and γ subunits suggest that direct G protein ligands could affect individual effector pathways and/or modify signaling kinetics with great specificity (5,8,9). The G protein regulatory (GPR) or GoLoco motif, for example, is a peptide guanine nucleotide dissociation inhibitor (GDI) which is implicated in receptor-independent signaling (10,11). Other recent advances include the identification of ligands for Gβγ that affect downstream signaling pathways using peptide (12) or small molecule (13) libraries.

*To whom correspondence should be addressed. richrob@usc.edu.
†These authors contributed equally to this work.
‡Present address: Goldyne Savad Institute of Gene Therapy, Hadassah University Hospital, P.O. Box 12000, Jerusalem, 91120, Israel
A selection for peptides that bind to Gα subunits yields several classes of signaling modulators: activators, inhibitors, and attenuators of G protein signaling.

Supporting Information Available: This material is available free of charge via the Internet.
In vitro peptide selection methods have been widely successful in isolating ligands for biological targets (14,15). Various proteins in the G protein signaling pathway have been targeted by selection libraries, including receptors and Gα and Gβγ subunits (8). mRNA display is a selection technique where each peptide in a library is covalently coupled with its encoding mRNA (16,17). Previously, we used mRNA display selection to identify a peptide (R6A) and its core motif (R6A-1) that bind with high affinity and specificity to the GDP-state of Gα subunits (18,19). R6A and R6A-1 act as GDIs and compete with Gβγ for binding to Gαi1 (18,19). We hypothesized that the 9-residue R6A-1 sequence could be used as a scaffold for developing new peptide ligands with different activities and/or specificities for Gα subunits. Here we design an mRNA display library based on the R6A-1 core motif and use in vitro selection to identify unique peptides that differentially modulate G protein signaling.

A DNA template was constructed to encode the R6A-1 peptide (DQLYWWEYL) flanked by random hexamers on each end (see Methods). Nucleotide incorporation was controlled such that each wild-type residue in the core motif was ~40–50% conserved (20). mRNA display selection was performed on N-terminally biotinylated Gαi1 (Nb-Gαi1) due to the previous finding that R6A-derived peptides bind preferentially to Nb-Gαi1 over the C-terminally biotinylated Cb-Gαi1 (18). Aluminum fluoride (AlF) was supplemented into the selection buffer to attempt to select for peptides specific for the GDP-AlF state of Gαi1, a transition state mimic of GTP hydrolysis (21,22). AlF (either as AlF3 or AlF4−) has been shown to activate Gα subunits—preventing association with Gβγ heterodimers—and GAPs have been shown to bind exclusively to this transition state mimic. Six rounds of selection were performed and significant binding was observed by the third round (Fig. 1a). Based on the starting library complexity of ~2 × 1013 and a maximum enrichment of 10,000-fold per round, we estimate that the third round input pool contained more than 100,000 unique, Gαi1-binding peptide sequences. To enrich for peptides specific for the AlF-bound state of Gαi1, the fifth and sixth round pools were pre-cleared against Gαi1-GDP prior to selection against Gαi1-GDP-AlF.

DNA sequencing of clones from the sixth round pool showed that the core 9-mer was primarily conserved, except for a preference for Leu instead of Gln in the second position (Fig. 1b and Table 1 in the Supporting Information). The random hexamer regions showed no obvious sequence conservation, although the residues directly flanking the core motif favored several amino acids including Leu, Asp, and Glu. In vitro binding assays with individual clones revealed that the peptides bind ~1–40% to immobilized Gαi1-GDP-AlF (Fig. 1c). The wide range of binding may suggest that the selection was not complete, or that specificity to the AlF-bound state of Gαi1 produces a trade-off in overall binding.

Binding assays of individual peptides to Gαi1-GDP in the presence or absence of AlF show that most peptides favor the GDP-bound state (Fig. 1c). Hence, the selection identified peptides with a loss of specificity, compared with the original R6A sequence. Only one peptide, AR6-04, exhibited better binding in the presence of AlF, but this peptide appears to have significantly lower affinity for Gαi1 than other peptides. Because the selected peptides bind both states, pre-cleaving the fifth and sixth round pools on Gαi1-GDP may have removed the highest affinity peptides while only marginally enriching for specificity to Gαi1-GDP-AlF.

AR6-04 and AR6-05 exhibited the highest AlF/GDP-state binding ratios for Gαi1 and were synthesized for further characterization. Their affinities to immobilized Gαi1-GDP were determined by surface plasmon resonance (SPR). Corresponding with the lower binding seen in the in vitro assays, the K_D of AR6-04 for Gαi1-GDP appears to be >10 µM. Conversely, AR6-05, with an apparent K_D of ~10 nM, is the highest affinity Gα-directed peptide that we have tested, binding more than 6-fold better to Gαi1-GDP than our previously described R6A peptide, and more than 20-fold better than the R6A-1 core motif (18). While R6A and R6A-1...
show clear 1:1 bimolecular binding kinetics, AR6-05 binding data were well fit only with a more complex kinetics model (Fig. 1 in the Supporting Information).

R6A and R6A-1 were previously shown to compete with Gβγ heterodimers for binding to Ga11 in vitro (18,19). Binding of radiolabeled Gβ1γ2 to immobilized Ga11 in the presence or absence of peptides was performed to determine the peptide effects on Gβγ association. AR6-05 competes with Gβγ for binding to Ga11 (Fig. 2a). Like the R6A peptide, binding of Ga11 to immobilized AR6-05 precludes Gβγ association (Fig. 2c).

Surprisingly, AR6-04 appears to enhance Gβ1γ2 binding to Ga11. Several in vitro assays were performed that support this observation: (1) labeled Gβγ shows higher binding to immobilized Ga11 in the presence of free AR6-04 peptide (Fig. 2b), (2) labeled AR6-04 peptide shows 66% higher binding to immobilized Ga11 in the presence of Gβ1γ2, and (3) experiments with labeled Ga11β1γ2 show that immobilized AR6-04 is able to pull down all three subunits (Fig. 2c).

To test the activity of the peptides in a cellular context, we used a HEK293 cell line expressing the inwardly rectifying potassium channels, GIRK1 and 2, and the dopamine D2S GPCR. Previous cell culture studies have shown that, similar to the G protein specificity observed in vivo, only Gj6βγ-coupled receptors activate GIRK channels (23,24). In these cells, GIRK channels are the dominant downstream effectors of released Gβγ subunits. The GPR consensus peptide (10) was previously shown to attenuate signaling events after an initial agonist application, without affecting basal GIRK activity (25). The authors hypothesized that the GPR peptide is able to interact with Ga subunits only after an initial activation, which frees Ga for peptide binding. We confirmed these results with the L19GPR peptide, which differs from the GPR consensus at a redundant residue (10,18,26). In the absence of peptide, the kinetics of channel deactivation (τ, deactivation time constant) are similar after short (τb) followed by long (τd) dopamine applications (10.6 ± 1.9 s, n = 10 and 13.7 ± 3.4 s, n = 7, respectively, p = 0.68, Fig. 3a). In contrast, L19GPR increased τb significantly compared with controls (Fig. 3b and c). GIRK basal activity returned to its initial values after ~2 min from the dopamine washout, indicating that the L19GPR peptide effect is transient, since a persistent effect should have resulted in higher basal activity.

R6A exhibited similar effects to the L19GPR peptide. R6A increased τb moderately while the negative control peptide C-GPR had no effect (Fig. 3d). R6A had minimal effect on the basal GIRK channel activity (n = 7, p = 0.18) which suggests that, like the GPR peptide, R6A is unable to dissociate Gaβγ heterotrimers in vivo. In contrast to R6A, intracellular application of AR6-05 increased basal activity dramatically, suggesting that AR6-05 actively dissociates Gβγ from Ga in vivo (Fig. 4).

AR6-04 had no effect on the deactivation kinetics (Fig. 3d), but instead directly reduced basal GIRK activity (Fig. 4). This coincides with the in vitro binding data, where AR6-04 stabilizes a heterotrimer complex and presumably reduces the active Gβγ available for GIRK channel activation. It is not clear how AR6-04 stabilizes the heterotrimer despite being selected against the Ga subunit alone. The peptide sequence differs greatly from the original R6A-1 core motif. The flanking regions of AR6-04, however, share modest sequence similarity to the short Gβγ-binding motifs previously identified (12), suggesting that other molecules that shut down G protein signaling may be constructed by fusing known Ga- and Gβγ-specific ligands.

The R6A-1 based peptide library should be useful for the selection of peptides that are specific for various G protein subclasses or nucleotide-bound states. Given the large number of Ga11 binding peptides identified here, unique functions, such as specificity for Ga11 over other Ga subunits, may have yet to be identified. While it is clear that AR6-04 and AR6-05 affect GIRK channel activity—an effector of Gβγ—the peptide effects on Ga-regulated pathways and Ga nucleotide-bound states have yet to be determined. For example, because GAPs have been
shown to catalyze GTP hydrolysis by stabilizing a transition state (21, 22), selected peptides that bind \( \text{G}_\alpha_{i1} \text{-GDP-AlF} \) may act as small molecule GAPs. Although further technological advances are necessary for the facile conversion of peptides to therapeutics, determining the mechanism of action of the AR6-04 and AR6-05 peptides will facilitate the rational design of more potent modifiers of G protein signaling for use as biological tools and potential drug leads.

### Methods

#### Materials

Human cDNA clones for G proteins were obtained from the UMR cDNA Resource Center (http://www.cdna.org) in the pcDNA3.1+ vector (Invitrogen). The \( \text{G}_\gamma_2 \) cDNA vector encoded an N-terminal HA tag. Anti-HA mAb (clone HA-7) was obtained from Sigma. Expression of \( \text{S}^{35}\text{S}-\text{Met} \)-labeled G proteins by \textit{in vitro} translation was performed as described previously (19).

#### mRNA display selection

The doped R6A-1 library was constructed by PCR amplification of oligo 115.1 \([5’-\text{AGC AGA AGT GTA ACC GCC (SNN)}_6 (\text{S13}) (\text{S641}) (\text{S542}) (\text{S521}) (\text{S521}) (\text{S641}) (\text{S543}) (\text{S642}) (\text{SNN})_6 \text{CAT TGT AAT TGT AAA TAG TAA TTG TCC C; 1 = 7:1:1, 2 = 1:7:1:1, 3 = 1:1:7:1, 4 = 1:1:1:7, A:C:G:T; 5 = 9:1, 6 = 1:9, C:G; N = A, C, G, OR T; S = C OR G (ratios have been adjusted for synthesis incorporation rates)]\) with primers 47T7FP (5’-\text{GGA TTC TAA TAC GAC TCA CTA TAG GGA CAA TTA CTA TTT ACA ATT AC}) and 22.9 (5’-\text{AGC AGA CAG ACT AGT GTA ACC G}) to produce dsDNA encoding M-X\( _6 \)-DQLYWWEYL-X\( _6 \)-GGYTSLSA, with the core 9-residues conserved ~40–50%. Sequencing of randomly chosen clones from the initial pool revealed a distribution of wild-type residues in the core motif that agreed with theoretical calculations (data not shown). \textit{In vitro} transcription, ligation of the mRNA to the puromycin linker, and purification of the RNA-F30P template were performed as described previously, except that the splint oligo 23.8 \((5’-\text{TTT TTT TTT TTN AGC AGA CAG AC})\) was used for the ligation reaction (18). RNA-peptide fusions were prepared, purified on oligo-dT cellulose, reverse-transcribed with oligo 22.9, and selected against immobilized N-terminally biotinylated \( \text{G}_\alpha_{i1} \) (Nb-\( \text{G}_\alpha_{i1} \)) as described previously using a modified selection buffer \([25 \text{mM HEPES-KOH at pH 7.5, 150 mM NaCl, 0.05% (v/v) Tween 20, 1 mM } \beta \text{-mercaptoethanol, 10 } \mu \text{M GDP, 20 } \mu \text{M EDTA, 5 mM MgCl}_2, 10 \text{ mM NaF, 25 } \mu \text{M AlCl}_3, 0.05\% \text{ (w/v) BSA, and 1 mg mL}^{-1} \text{ yeast tRNA\} (18).}\)

#### RNA-peptide fusion binding assay

Purified, RNase-treated mRNA display peptide fusions of individual clones were assayed for binding as described previously (27). Briefly, aliquots of \( \text{S}^{35}\text{S}-\text{labeled} \) fusions were added to ~15 µL of Nb-\( \text{G}_\alpha_{i1} \) (~15 µg protein) on streptavidin agarose (immobilized NeutrAvidin on agarose, Pierce) in 1 mL of selection buffer. After binding for 1 h, the matrices were washed with 3 x 0.6 mL of selection buffer in a 0.45 µm cellulose acetate spin filter (CoStar Spin-X, Corning). Input \( \text{S}^{35}\text{S} \) counts for binding assays were determined by scintillation counting of the washes and the matrix. Bound \( \text{S}^{35}\text{S} \) counts were divided by the input counts to calculate the fraction bound. Binding of RNase-treated peptide fusions to the immobilization matrix alone was less than 0.001. Assays for binding to \( \text{G}_\alpha_{i1} \text{-GDP} \) were performed in selection buffer without AlF.

#### \textit{in vitro} peptide studies

Peptides were synthesized with the first 3 residues of the C-terminal constant tag (GGY) and purified by Bio-Synthesis, Inc. Three additional C-terminal lysines were added to the AR6-04
peptide to enhance solubility. SPR affinity measurements were made on immobilized \( \text{Nb-G} \alpha_{i1} \) as described previously (18). Peptide effects on \( \text{G} \beta\gamma \) association with immobilized \( \text{Nb-G} \alpha_{i1} \) were assayed by mixing an aliquot of \( 35^{S} \)-labeled \( \text{G} \beta_{1} \gamma_{2} \) with ~15 µL of immobilized \( \text{Nb-G} \alpha_{i1} \) in 1 mL of selection buffer without AlF. After rotating at 4 °C for 1 h, samples were washed with 3 × 0.6 mL of the binding buffer in a spin filter, as described above. Binding was determined by scintillation counting and scaled to the amount of \( \text{G} \beta\gamma \) pulled down in the absence of peptide. Data are background subtracted from binding to matrix without immobilized \( \text{G} \alpha_{i1} \) (~10% of overall binding). AlF reduced \( \text{G} \beta_{1} \gamma_{2} \) pull down on \( \text{Nb-G} \alpha_{i1} \) to ~50%.

**\( \text{Ga} \beta\gamma \) heterotrimer immunoprecipitation**

AR6-04 and AR6-05 were expressed as MBP fusion proteins and immobilized by random amine coupling on CNBr-Sepharose 4B (GE Healthcare) as described previously (19). \( 35^{S} \)-labeled \( \text{Ga} \beta\gamma \) heterotrimer was immunoprecipitated with anti-HA monoclonal antibody and protein G-sepharose, or pulled down on immobilized MBP as described previously (19). Recovered proteins were separated by SDS-PAGE. Gels were imaged by autoradiography (Storm PhosphorImager, GE Healthcare).

**Electrophysiology**

We used HEK293 cell lines stably expressing GIRK1, GIRK2a, and the \( \text{G} \)i/o-coupled dopamine (\( \text{D}_{2s} \)) receptor (23). The pipette solution contained 107 mM KCl, 1.2 mM MgCl\(_2\), 1 mM CaCl\(_2\), 10 mM EGTA, 5 mM HEPES at pH 7.4, 2 mM MgATP, and 0.3 mM Na\(_2\)GTP. Peptides were added to the pipette solution immediately prior to recording. The final DMSO concentration was 0.5% (v/v) or less. The bath solution contained 2.6 mM CaCl\(_2\), 1.2 mM MgCl\(_2\), 5 mM HEPES at pH 7.4, and either 140 mM KCl (High-K\(^+\)) or 140 mM NaCl (Zero-K\(^+\)). Membrane currents were recorded in a whole-cell patch-clamp mode with an Axopatch 200B amplifier (Axon Instruments), and a patch pipette resistance of 2.5–4.5 M\( \Omega \). Data were filtered at 1 kHz and digitized at 5 kHz. Cell capacitance was 12–18 pF, and series resistance (5–20 M\( \Omega \)) was at least 75% compensated on-line. Current recording was acquired after equilibration for ~5 min in gap-free mode at ~80 mV. Dopamine (2 µM, Sigma) was applied in bath solution via an \( \text{N}_2 \)-pressurized perfusion system (ALA Scientific Instruments).

**Data analysis**

Data acquisition and analysis was done by a Digidata 1200A interface (Axon Instruments) and pClamp 8.2 and Microcal Origin 6.0 software. The deactivation time constants (\( \tau \)) were determined in pClamp (standard exponential). Currents were averaged over 17 ms to reduce 60 Hz background noise. All data are presented as mean ± s.e.m.. Statistical significance was determined by non-paired, two-tailed student’s t tests. In figures: *, \( p < 0.05 \); **, \( p < 0.01 \); ***, \( p < 0.0001 \).

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

**Acknowledgments**

We thank D.S. Waugh (National Cancer Institute at Frederick) for providing the original pDW363 vector and P. J. Bjorkman for the use of the Biacore 2000 instrument. This work was supported by funding from the NIH and the Beckman Foundation (R.W.R.), the Howard Hughes Medical Institute and NIMH (L.Y.J., in the Silvio Conte Center of Neuroscience at UCSF), the European Molecular Biology Organization (O.W.), and a DOD National Defense Science and Engineering Graduate Fellowship (W.W.J.).
References


Figure 1.
*In vitro* selection targeting $\mathrm{G}_i_1$-GDP-AlF. (a) Fraction of $^{35}\mathrm{S}$-labeled mRNA display pools from each round of selection bound to immobilized $\mathrm{G}_i_1$-GDP-AlF and recovered by elution with SDS. The inputs for the fifth and sixth rounds were pre-cleared against $\mathrm{G}_i_1$-GDP prior to selection. (b) Sequences of peptides used in *in vitro* studies. The region corresponding to the R6A-1 core motif is boxed (grey). The C-terminal constant region is not shown. (c) Binding of individual, RNase-treated, $^{35}\mathrm{S}$-labeled mRNA display fusions to $\mathrm{G}_i_1$-GDP or $\mathrm{G}_i_1$-GDP-AlF. Except for AR6-04, all tested peptides have a preference for binding to $\mathrm{G}_i_1$-GDP.
Figure 2.
AR6-04 and AR6-05 Gαi1-binding peptides differentially affect Gβγ association. (a) and (b) Binding of 35S-Met–labeled Gβ1γ2 to immobilized Gαi1 in the presence or absence of AR6-05 (20 µM) or AR6-04 (33 µM). AR6-05 competes with Gβγ for association to Gαi1 (n = 4, p = 0.0050) while AR6-04 increases Gβγ binding (n = 3, p = 0.041). DMSO (~1%, vol/vol) had no effect on Gβγ binding (n = 3, p = 0.50). (c) Binding of 35S-Met–labeled Gαi1β1γ2 to immobilized peptides. Anti-hemagglutinin (HA) antibody immunoprecipitates the HA-tagged Gγ2 subunit and confirms the presence of reconstituted heterotrimers. Immobilized maltose-binding protein (MBP) fails to pull down G proteins while binding of Gαi1 to immobilized AR6-05–MBP completely precludes Gβ1γ2 association. AR6-04–MBP, however, pulls down
the intact heterotrimer. The control MBP lane is shown again at the same contrast as the AR6-04 lane for comparison.
Figure 3.
Effect of intracellular application of peptides on GIRK deactivation kinetics. (a) HEK293 cells stably expressing GIRK1 and 2 and the dopamine receptor D_2s were recorded by whole-cell patch-clamp (see Methods). Zero-K^+ buffer (red bar) was perfused for 4 sec to determine GIRK basal activity. Application of dopamine for 4 and 30 sec (green bars) activated GIRK currents. Dopamine washout was followed by GIRK channel deactivation. τ_a and τ_b are the GIRK deactivation time constants following the short and long dopamine applications, respectively. The dotted line represents 0 pA. (b) Superposition of representative current traces of cells recorded in the presence of 2 µM of the control peptide L19GPR-R23L (black) or the L19GPR peptide (red). L19GPR-R23L is a negative control peptide which contains a mutation to a
critical Arg residue (26). Current traces were normalized to cell membrane capacitance and current amplitude in Zero-K+ buffer was subtracted from current traces in High-K+ buffer. (c) L19GPR (2 µM) increases \( \tau_b \) after prolonged dopamine application \( (n = 7, p = 3.9 \times 10^{-5}) \) while the control L19GPR-R23L peptide (2 µM) has no effect \( (n = 2, p = 0.71) \). \% \Delta \tau_{\text{deac}} \) is the percentage change of \( \tau_b \) from \( \tau_a \). (d) R6A (100 µM) moderately increases \( \tau_b \) \( (n = 4, p = 0.0065) \) while AR6-04 (40 µM, \( n = 5, p = 0.49) \) and the control C-GPR peptide (100 µM, \( n = 5, p = 0.44) \) have no effect. AR6-05 (40 µM) appears to increase \( \tau_b \) \( (n = 5, p = 0.13) \) but there is significantly increased error in the kinetics measurements likely due to the effect that AR6-05 has on basal GIRK activity. In (c) and (d), the control contains <0.5% (v/v) DMSO.
Figure 4.
Intracellular application of 40 µM AR6-05 or AR6-04 increases (n = 4, p = 0.0046) or decreases (n = 5, p = 0.027) basal GIRK currents, respectively. Current densities are determined by normalization with the individual cell capacitance. The control contains <0.5% (v/v) DMSO.